WHAT'S NEW | UPCOMING EVENTS
News
Notice: Board Proceedings in the Remicade Matter
OTTAWA, February 5, 2003: The Patented Medicine Prices Review Board has amended its schedule in the Remicade matter as follows:
Pre-Hearing Conference
Tuesday, February 11, 2003
9:30 a.m.
Standard Life Centre
333 Laurier Avenue West
18th Floor
Hearing Room 2
Hearing
Commencing on Tuesday, April 22, 2003
Location to be determined
The purpose of the hearing is to determine whether, under sections 83 and 85 of the Patent Act, Schering
is selling or has, while a patentee, sold the medicine known as Remicade in any market in Canada at a price that, in the Board's opinion, is or was excessive; and,
if so, what order, if any, should be made.
Remicade is sold pursuant to a Notice of Compliance issued by Health Canada on June 6, 2001 for the treatment of Crohn's disease and to a Notice of Compliance issued on September 27, 2001 for the treatment of rheumatoid arthritis.
Notice of Hearing (PDF - 57kb)
Schedule of Events (PDF - 22kb)
For any additional information on this matter, please contact the Secretary of the Board.
Sylvie Dupont
Secretary of the Patented Medicine Prices Review Board
Standard Life Centre
333 Laurier Avenue West
Suite 1400
Ottawa, Ontario K1P 1C1
Toll-free number: 1-877-861-2350
Direct line: (613) 954-8299
Fax: (613) 952-7626
E-mail: sdupont@pmprb-cepmb.gc.ca
Website: www.pmprb-cepmb.gc.ca
Return to News
